Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fibrinogen therapy during craniosynostosis repair
NL-OMON41510Phase 3Active, not recruiting
- Sponsor
- Erasmus MC
- Start
- Sep 2012
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of Fibrinogen human in Craniosynostosis, sponsored by Erasmus MC. Primary endpoint: Amount of intraoperative and postoperative transfusions required. Started Sep 2012; status: active, not recruiting.
02
Drugs
Fibrinogen human
03
Conditions
Craniosynostosis
Beyond the preview
Go deeper on NL-OMON41510.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41510.